Chinese firm acquires selected Asian rights to Kinex's oncology candidate
This article was originally published in Scrip
Executive Summary
Xiangxue Pharmaceuticals has acquired rights in several Asian markets to Kinex Pharmaceuticals' preclinical stage brain tumour drug candidate KX02, in a deal indicative of Chinese firms' rising interest in licensing novel foreign development projects and technology.